Effectiveness of therapy for endometriosis-associated pelvic pain resistant to surgical treatment

Summary: to evaluate the efficacy and safety of dienogest therapy for 24 weeks in patients with endometriosis-associated pelvic pain resistant to surgical treatment.Material and methods. The study included 126 patients aged 33-40 years with external genital endometriosis confirmed by laparoscopy and morphological examination (NGE; ICD-10-N80. 1, 80.2, 80.3, 80.4) and with pelvic pain that occurred 3-6 months after surgical treatment of NGE (ICD-10 N94.8 "Pain and other conditions associated with female genital organs and menstrual cycle"). The participants were stratified into three groups depending on the severity of the pain syndrome according to the verbal rating scale (VAS; Verbal Analog Scale). Group 1 included patients with a VAS pain score of 10-40 mm, group 2-41-70 mm, and group 3 more than 71 mm. Patients of all three groups were prescribed the drug Zafrilla (dienogest 2 mg/day) for a course of 24 weeks (according to the current instructions